



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001:2008 Certified Company

CIN No. L24239MH1988PLC047759

SYNCOM/SE/2017-18

16th May, 2017

online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Limited.
Dalal Street, Fort,
MUMBAI-400001

BSE CODE: 524470

Sub: Corporate Announcement u/r 29(1)(a) of the SEBI (LODR) Regulations, 2015 for intimation of the 01/2017-18 Board Meeting for consideration and approval of the Audited Financial Results for the quarter/year ended 31st March 2017 and recommendation of Dividend, if any.

Dear Sir,

We are pleased to inform you that the 01/2017-18 Meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday, the 30th day of May 2017 at 4.00 P.M.** at the Corporate office of the Company to consider and approve the following businesses along with other routine businesses:

1. To consider & approve the Standalone & Consolidated Audited Financial Results of the Company for the Quarter/Year Ended 31st March, 2017.
2. To take on record the Audit Report submitted by the Auditors for the Financial Results of the Company for the Quarter/Year ended 31st March, 2017.
3. To recommend dividend on Equity Shares of Re. 1/- each for financial year 2016-17, if any.

The Notice of the Board Meeting will be published in widely circulated English and Marathi (Vernacular) newspaper.

You are requested to please take on record above said information for your reference.

Thanking you,
Yours faithfully,
For, SYNCOM FORMULATIONS (INDIA) LTD.


CS PRACHI RATHORE
COMPANY SECRETARY &
COMPLIANCE OFFICER



Bringing a smile on every face...